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Brain Derived Neurotrophic Factor alterations in patients with suicide risk 
A Systematic Review and Meta-analysis 
Abstract 
Brain Derived Neurotrophic factor levels (BDNF) have been investigated in the context of hormonal and 
endocrine biomarkers of suicide risk. Cross-sectional studies have compared BDNF between patients with 
versus without suicide risk. Several studies have found lower BDNF levels in patients with suicide risk 
compared to patients without, while few studies did not report significant differences. This study aims to 
systematically review and meta-analyze data to examine differences for (plasma and serum) BDNF levels 
between patients with versus without suicide risk.  The primary outcomes will be measured as the mean or 
standardized mean differences for peripheral serum or plasma blood concentrations of BDNF. Further 
analyses will encompass subgroup analyses and meta-regression assessing the impact of factors such as 
age, sex, body mass index, diagnosis, psychotropic medications, symptom severity and publication year. 
Results will be published in a peer-reviewed journal.  
 
 
 
Introduction: 
  
Numerous factors have been studied in the context of risk of suicidal behavior. Research has shown that 
the majority of fatal and non-fatal suicidal behaviors co-occur with the presence of a psychiatric illness. 
The neurochemical mechanisms related to suicidal behaviors are particularly complex and poorly 
understood.1 Brain Derived Neurotrophic Factor (BDNF) is found to play a critical role in several neural 
processes, including/by enhancing neurogenesis, neurotransmission, and neuroplasticity.2,3 BDNF is a 
protein that is primarily produced in the central nervous system. The protein is unique, however, as it has 
been shown to cross the blood-brain barrier. The levels of BDNF in the bloodstream are reflective of those 
in the brain.2 Evidence shows significantly lower levels of BDNF in patients with a psychiatric disorders 
compared to healthy controls. 4–7 Moreover, lower BDNF levels were reported in patients who had 
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previously attempted suicide compared to patients who had not.4,6,7 However, available data are 
inconsistent. The aim of this study is to systematically review and meta-analyze BDNF levels in patients 
with suicide risk compared to patients without suicide risk in order to provide insight on the 
pathophysiology of suicide risk.  
 
Methods 
Search strategy 
We will perform a systematic review and meta-analysis. Our search will include Google Scholar, 
Pub Med, and Embase search engines for all studies predating January 12th 2019. 
Inclusion & exclusion criteria 
Cross sectional and case control trials with BDNF assessments in patients with and without suicide 
risk or healthy controls. 
Patient Population 
Patients with and without suicide risk. 
Control 
Patient control and healthy control groups without suicide risk. 
Main Outcome 
Standardized mean differences or mean differences between patients with and without suicide risk. 
Secondary Outcome 
Effects of age, sex, body mass index (BMI), diagnosis, medications, symptom severity. 
Data extraction 
Data will be extracted independently by two of the authors based on PRISMA guidelines statement 
(12). 
Risk of bias assessment 
The studies’ risk of bias will be assessed by two authors using the modified version of Newcastle-
Ottawa scale for cross-sectional studies. 
Statistical analysis 
Fixed and random effect inverse variance meta-analysis will be performed. Results will be 
summarized using mean differences (MD) or standard mean differences (SMD) with a 95% 
confidence interval (CI). The heterogeneity variance parameter (τ2) will be measured by using the 
DerSimonian-Laird estimator.  Additionally, I2 statistic will be used to further investigate the 
heterogeneity by measuring the variability within the analysis. The analysis will be conducted in 
meta package of R v.3.6.1. 
Subgroup and meta-regression analyses 
Subgroup and meta-regression analyses will be implemented to further investigate the role of 
moderators/confounders, such as age, sex, BMI, diagnosis, psychotropic medications, symptom 
severity and year of publication. 
Dissemination plans 
Results will be published in a peer-reviewed journal. 
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